№ files_lp_4_process_3_130194
File format: docx
Character count: 2263
File size: 22 KB
This is a resource document listing potential side effects of Tocilizumab for cancer treatments, designed for research staff to reference during clinical trials.
Year:
2025
Region / City:
USA
Theme:
Cancer treatment, Clinical trials
Document Type:
Side effect table
Organization / Institution:
NCI CIRB
Author:
NCI CIRB
Target Audience:
Research staff, Clinical trial professionals
Approval Date:
N/A
Date of Last Update:
December 5, 2025
Period of Validity:
N/A
Price: 8 / 10 USD
The file will be delivered to the email address provided at checkout within 12 hours.
The file will be delivered to the email address provided at checkout within 12 hours.
Don’t have cryptocurrency yet?
You can still complete your purchase in a few minutes:- Buy Crypto in a trusted app (Coinbase, Kraken, Cash App or any similar service).
- In the app, tap Send.
- Select network, paste our wallet address.
- Send the exact amount shown above.
The final amount may vary slightly depending on the payment method.
The file will be sent to the email address provided at checkout within 24 hours.
The product description is provided for reference. Actual content and formatting may differ slightly.
Year:
2025
Organization:
NHS England, Medicines Procurement and Supply Chain (MPSC)
Type of document:
Invitation to offer / Procurement document
Project title:
NHS National Framework for the supply of Tocilizumab Injection
Offer reference number:
CM/TNS/25/5723
Period of framework:
1 March 2026 to 31 August 2027, with option to extend up to 24 months
Publication date:
7 October 2025
Submission deadline:
5 November 2025, 13:00
Platform for submission:
Atamis / Central Digital Platform
Requirements:
Evergreen assessment, Carbon Reduction Plan, registration on Central Digital Platform
Author / contact:
Katie Noonan, Medicines Procurement Coordinator, NHS England
Region:
United Kingdom
Audience:
Suppliers eligible to participate in NHS procurement
Type of procurement:
Medicines supply
Year:
2026
Region / City:
Australia
Theme:
Pharmaceutical
Document Type:
Submission for approval
Organization:
PBAC (Pharmaceutical Benefits Advisory Committee)
Author:
Roche Products Pty Ltd
Target Audience:
Medical Practitioners
Effective Period:
Ongoing
Approval Date:
November 2018
Date of Last Revision:
2026
Category / Program:
GENERAL – General Schedule (Code GE)
Prescriber type:
Medical Practitioners
Condition:
Severe active juvenile idiopathic arthritis
PBS Indication:
Severe active juvenile idiopathic arthritis
Treatment phase:
Initial treatment, Continuing treatment
Restriction Level / Method:
Restricted benefit, Authority Required
Clinical criteria:
No more than 16 weeks of treatment allowed under restriction
Prescriber Instructions:
Specific dosage requirements based on patient weight
Comparator:
IV tocilizumab, etanercept, adalimumab
Sponsor hearing:
None
Consumer comments:
None
Clinical trials:
JIGSAW 117 trial
Note:
Year
Year:
2026
Region / city:
UK
Subject:
Electric Vehicle Charge Points, Heat Pumps, and connection procedures
Document Type:
Application form
Organization / institution:
Distribution Network Operators (DNOs)
Author:
Not specified
Target audience:
Individuals or entities installing electric vehicle charge points (EVCP) or heat pumps (HP)
Effective Period:
Ongoing
Approval Date:
Not specified
Modification Date:
Not specified
Year:
N/A
Region / City:
N/A
Theme:
Foster Care, Kinship Care, Child Welfare
Document Type:
Form
Agency / Institution:
N/A
Author:
N/A
Target Audience:
Agency Representatives, Foster Parents, Kinship Parents, Social Workers
Period of Validity:
N/A
Approval Date:
N/A
Amendment Date:
N/A
Contextual Description:
A form used for documenting and assessing the well-being and progress of children in various care placements, such as foster, therapeutic foster, or residential care.
Year:
2019
Region / city:
Geneva
Subject:
Madrid System for International Registration of Marks
Document type:
Working Group Report
Organization:
International Bureau
Author:
International Bureau
Target audience:
Member States and relevant stakeholders of the Madrid System
Period of validity:
Not specified
Date of approval:
May 21, 2019
Date of changes:
Not specified
Note:
Contextual description
Year:
2023
Region / City:
Forth Valley
Topic:
Incident Reporting, Controlled Drugs
Document Type:
Report Form
Organization / Institution:
NHS Forth Valley
Author:
Kirsty Peacock, Scott Mitchell
Target Audience:
NHS staff, Contractors
Period of Validity:
Not specified
Approval Date:
Not specified
Date of Changes:
Not specified
Year:
Not provided
Region / City:
Not provided
Theme:
Research methodology
Document type:
Academic paper
Organization:
AGH University of Science and Technology Press
Author:
Not specified
Target audience:
Researchers, academics, students
Period of validity:
Not specified
Approval date:
Not provided
Date of amendments:
Not provided
Year:
2024
Region / city:
USA
Topic:
Medical, Oncology
Document Type:
Educational Materials
Organization:
NCI CIRB
Author:
NCI
Target Audience:
Research staff, IRB members, clinical trial participants
Period of Validity:
Not specified
Approval Date:
Not specified
Date of Changes:
Not specified
Year:
2023
Region / City:
United States
Topic:
Medicine, Side Effects, Clinical Trials
Document Type:
Educational Material
Organization:
NCI CIRB
Author:
N/A
Target Audience:
Research Staff, Clinical Trial Staff
Period of Validity:
N/A
Approval Date:
N/A
Modification Date:
N/A
Year:
2024
Region / city:
USA
Topic:
Medical Information, Cancer Treatment
Document Type:
Educational Resource
Author:
National Cancer Institute (NCI)
Target Audience:
Research staff, Clinical trial participants, Healthcare professionals
Action Period:
Ongoing
Approval Date:
Not specified
Amendment Date:
Not specified
Year:
2022
Region / City:
US
Topic:
Medical, Pharmacology
Document Type:
Research Resource
Organization / Institution:
National Cancer Institute (NCI)
Author:
Not specified
Target Audience:
Research staff, clinical trial personnel
Period of validity:
Not specified
Approval Date:
Not specified
Date of changes:
Not specified
Year:
2024
Region / city:
USA
Theme:
Medical / Oncology
Document type:
Side Effect Table
Organization:
NCI CIRB
Target Audience:
Research staff, Clinical trial participants
Period of validity:
N/A
Approval date:
N/A
Modification date:
N/A
Year:
2023
Region / City:
United States
Topic:
Side effects of chemotherapy
Document type:
Educational Material
Organization / Institution:
National Cancer Institute (NCI)
Author:
Not specified
Target audience:
Research staff, clinical trial participants
Effective period:
Not specified
Approval date:
Not specified
Date of revisions:
Not specified
Year:
2025
Region / city:
United States
Topic:
Side effects of cancer therapy
Document type:
Patient Educational Material
Author:
National Cancer Institute
Target audience:
Research staff, clinical trial participants
Period of validity:
N/A
Approval date:
N/A
Date of amendments:
N/A
Year:
2025
Region / city:
US
Theme:
Cancer Treatment, Side Effects
Document Type:
Medical Resource
Organization:
National Cancer Institute (NCI)
Author:
Not specified
Target Audience:
Research Staff, Medical Professionals
Period of Validity:
Not specified
Approval Date:
Not specified
Date of Changes:
November 13, 2025
Year:
2023
Region / City:
United States
Topic:
Oncology, Pharmacology
Document Type:
Medical Information
Author:
NCI CIRB
Target Audience:
Clinical Research Staff
Period of Validity:
Indefinite
Approval Date:
Not Approved
Date of Changes:
March 22, 2023
Year:
2026
Region / City:
N/A
Topic:
Consultant Contract DBE Information
Document Type:
Form
Institution / Organization:
Caltrans
Author:
N/A
Target Audience:
Consultants, Local Agencies, Caltrans
Effective Period:
N/A
Approval Date:
N/A
Amendment Date:
N/A